About the Company
We do not have any company description for Kiromic Biopharma, Inc. at the moment.
Exchange
OTC
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Kiromic Biopharma, Inc.
Kiromic BioPharma, Inc. (KRBP) - Yahoo Finance
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01 HOUSTON, October 08, 2024--Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the ...
Kiromic BioPharma, Inc. Rings the Closing Bell in Celebration of its ...
ABOUT THIS EVENT Kiromic BioPharma, Inc. (Nasdaq: KRBP) rings the Nasdaq Closing Bell remotely from across the country. Maurizio Chiriva-Internati, DBSc, PhDs, Chairman & CEO, rings the Closing ...
KRBP | Kiromic Biopharma Inc. Stock Price & News - WSJ
View the latest Kiromic Biopharma Inc. (KRBP) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Kiromic BioPharma Announces Uplisting to OTCQB Market
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND® artificial intelligence (AI) 2.0 target discovery engine to develop and ...
Kiromic BioPharma, Inc. Announces Closing of Public Offering
Kiromic BioPharma, Inc. is a target discovery and gene-editing company utilizing a state-of-the-art artificial intelligence (AI) platform focused on unleashing the power of the patient’s own ...
Kiromic BioPharma Inc Ordinary Shares KRBP - Morningstar
Check out our KRBP stock chart to see a history of performance, current stock value, and a timeline of financial events & indicators for a full analysis today.
Kiromic Biopharma secures $2M in convertible note financing
Kiromic BioPharma, Inc., a Delaware-based biotechnology company specializing in biological products, has entered into a financial agreement involving a secured convertible promissory note ...
SHAREHOLDER ALERT: Kiromic Biopharma, Inc. (KRBP) Officers and ...
SAN FRANCISCO, Nov. 8, 2022 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of Kiromic Biopharma, Inc. (NASDAQ: KRBP) relating ...
Kiromic BioPharma, Inc. (KRBP)
Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival HOUSTON, February 18, 2025--Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the ...
Similar Companies
Loading the latest forecasts...